DaVita Inc. (DVA): Price and Financial Metrics
DaVita Inc. (DVA)
Today's Latest Price: $88.28 USD
Updated Jun 5 4:10pm
Add DVA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 66 in Medical - Services
See all "A" rated Strong Buy stocks
DVA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for DVA is 5.9 -- better than 92.87% of US stocks.
- Over the past twelve months, DVA has reported earnings growth of 83.74%, putting it ahead of 87.46% of US stocks in our set.
- Davita Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 46.49%, greater than the shareholder yield of 93.72% of stocks in our set.
- Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are WYNN, LAMR, CE, OUT, and SYNH.
- DVA's SEC filings can be seen here. And to visit Davita Inc's official web site, go to www.davita.com.
DVA Stock Price Chart More Charts
DVA Price/Volume Stats
| Current price | $88.28 | 52-week high | $90.15 |
| Prev. close | $82.39 | 52-week low | $46.36 |
| Day low | $82.80 | Volume | 2,848,998 |
| Day high | $88.70 | Avg. volume | 1,454,169 |
| 50-day MA | $77.35 | Dividend yield | N/A |
| 200-day MA | $71.60 | Market Cap | 10.75B |
DaVita Inc. (DVA) Company Bio
DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.
DVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $88.28 | $201.33 | 153% |
We started the process of determining a valid price forecast for Davita Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Davita Inc ranked in the 69th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 154%. In terms of the factors that were most noteworthy in this DCF analysis for DVA, they are:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 46. Notably, its equity weight is greater than just 11.87% of US equities in the Healthcare sector yielding a positive free cash flow.
- Davita Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 3.4% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 148% |
| 1% | 150% |
| 2% | 153% |
| 3% | 155% |
| 4% | 158% |
| 5% | 160% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try NVO, QDEL, JAZZ, ABBV, and FTLF.
Loading social stream, please wait...